KR20040075096A - 유형ｉ 당뇨를 치료하기 위한 약제 제조용 멜라가트란의용도 - Google Patents

유형ｉ 당뇨를 치료하기 위한 약제 제조용 멜라가트란의용도 Download PDF

Info

Publication number
KR20040075096A
KR20040075096A KR10-2004-7011228A KR20047011228A KR20040075096A KR 20040075096 A KR20040075096 A KR 20040075096A KR 20047011228 A KR20047011228 A KR 20047011228A KR 20040075096 A KR20040075096 A KR 20040075096A
Authority
KR
South Korea
Prior art keywords
melagatran
pharmaceutically acceptable
acceptable derivative
kit
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2004-7011228A
Other languages
English (en)
Korean (ko)
Inventor
올레 코르스그렌
보 닐슨
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20040075096A publication Critical patent/KR20040075096A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-2004-7011228A 2002-01-23 2003-01-21 유형ｉ 당뇨를 치료하기 위한 약제 제조용 멜라가트란의용도 Withdrawn KR20040075096A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0200198-0 2002-01-23
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (1)

Publication Number Publication Date
KR20040075096A true KR20040075096A (ko) 2004-08-26

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7011228A Withdrawn KR20040075096A (ko) 2002-01-23 2003-01-21 유형ｉ 당뇨를 치료하기 위한 약제 제조용 멜라가트란의용도

Country Status (14)

Country Link
US (2) US7045502B2 (https=)
EP (1) EP1469874A1 (https=)
JP (1) JP2005516035A (https=)
KR (1) KR20040075096A (https=)
CN (1) CN100430089C (https=)
BR (1) BR0306798A (https=)
CA (1) CA2472241A1 (https=)
IL (1) IL162853A0 (https=)
MX (1) MXPA04007192A (https=)
NO (1) NO20043483L (https=)
NZ (1) NZ533749A (https=)
SE (1) SE0200198D0 (https=)
WO (1) WO2003061682A1 (https=)
ZA (1) ZA200405342B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
CN113164765B (zh) 2018-07-13 2026-03-20 维颂国际公司 凝血酶抑制剂、制剂及其用途
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
KR20240155390A (ko) 2022-02-17 2024-10-28 사나 바이오테크놀로지, 인크. 조작된 cd47 단백질 및 이의 용도
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
AU2024328949A1 (en) 2023-08-23 2026-03-12 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Also Published As

Publication number Publication date
CA2472241A1 (en) 2003-07-31
US7045502B2 (en) 2006-05-16
EP1469874A1 (en) 2004-10-27
IL162853A0 (en) 2005-11-20
US20050090424A1 (en) 2005-04-28
WO2003061682A1 (en) 2003-07-31
NZ533749A (en) 2006-02-24
SE0200198D0 (sv) 2002-01-23
CN100430089C (zh) 2008-11-05
BR0306798A (pt) 2004-12-07
NO20043483L (no) 2004-08-20
JP2005516035A (ja) 2005-06-02
US20060148720A1 (en) 2006-07-06
CN1729010A (zh) 2006-02-01
ZA200405342B (en) 2005-09-28
MXPA04007192A (es) 2004-10-29

Similar Documents

Publication Publication Date Title
Ozmen et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation
JP2001513576A (ja) 側副経路を介する補体活性化を阻害するためのプロセス
US7045502B2 (en) Use of melagatran for the manufacture of a medicament for the treatment of Type 1 diabetes mellitus
CN109640959A (zh) 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
JP4315908B2 (ja) デキストラン硫酸エステルの新規用途
JP2007504167A (ja) 抗組織因子抗体を用いる移植片の生存を向上する方法
Waegell et al. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection
Roberts et al. Effects of pulmonary ischemia-reperfusion on platelet adhesion in subpleural arterioles in rabbits
US8048411B2 (en) Co-transplantation of hepatic stellate cells and islet cells
RU2315621C2 (ru) Применение ингибитора или антагониста тканевого фактора
JP2003501346A (ja) 移植手術における新規な使用
CN114762725B (zh) 一种治疗糖尿病的方法
CN114762697B (zh) 用于治疗糖尿病的药物及方法
AU2003202192A1 (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
Yoshimatsu et al. The impact of allogenic blood transfusion on the outcomes of total pancreatectomy with islet autotransplantation
Chen et al. Platelet glycoprotein VI-dependent thrombus stabilization is essential for the intraportal engraftment of pancreatic islets
RU2758536C1 (ru) Способ снижения воспалительной гиперактивации нейтрофилов
Yang et al. Blocking the CC chemokine receptor 5 pathway by antisense peptide nucleic acid prolongs islet allograft survival
WO2022143905A1 (zh) 一种治疗糖尿病的药物及其方法
Mattke Targeting Toll-Like Receptor 4 Related Inflammation Using Small Molecule, TAK-242, to Attenuate Inflammatory Damage in Pancreatitis and Islet Transplantation
Mineo et al. Islet and pancreas transplantation
Lee Islet surface PEGylation attenuate the instant blood-mediated inflammatory reaction in intrahepatic islet transplantation
Ghoraishi Strategies to combat inflammation in pancreas and islet transplantation
Aiso et al. BENEFICIAL EFFECT OF FR167653, A p38 MITOGEN-ACTIVATED PROTEIN KINASE INHIBITOR, ON EARLY POST-TRANSPLANT DYSFUNCTION OF TRANSPLANTED ISLETS IN RATS RECEIVING A MARGINAL ISLET MASS.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040720

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid